European Commission Approves Gilead's Trodelvy® For Pre-Treated HR+/HER2- Metastatic Breast Cancer

-- Approval Based on Clinically Meaningful Overall Survival Benefit Demonstrated in the TROPiCS-02 Study in Pre-Treated HR+/HER2- Metastatic Breast Cancer vs. Physician’s Choice of Chemotherapy...

Related Keywords

Madrid ,Spain ,California ,United States ,Foster City ,Barcelona ,Comunidad Autonoma De Cataluna ,American ,Javier Cortes ,Eva Schumacher Wulf ,Global Health Status Quality Of Life ,Nasdaq ,College Of American Pathologists ,Head Of The International Breast Cancer Center ,National Comprehensive Cancer Network ,Exchange Commission ,Gilead Public Affairs ,Committee For Medicinal Products ,Gilead Sciences Inc ,Gilead Sciences ,American Society Of Clinical Oncology ,National Comprehensive Cancer Network Inc ,European Commission ,Medicinal Products ,International Breast Cancer Center ,Bill Grossman ,Senior Vice President ,Therapeutic Area Head ,Chief Editor ,Metastatic Breast Cancer ,Global Health ,Spain Scale ,National Comprehensive Cancer ,Clinical Practice Guidelines ,Boxed Warning ,Important Safety ,Response Evaluation Criteria ,Solid Tumors ,American Society ,Clinical Oncology ,American Pathologists ,Safety Information ,Marketing Authorization Application ,Withhold Trodelvy ,Infusion Related Reactions ,Adverse Reactions ,Fetal Toxicity ,Prescribing Information ,Private Securities Litigation Reform Act ,Quarterly Report ,Breast Cancer Living ,Practice Guidelines ,Breast Cancer Version ,Markets ,